过渡期生长激素缺乏症的管理

成胜权

doi:10.7499/j.issn.1008-8830.2309173

PDF(553 KB)

HTML

中国当代儿科杂志 ›› 2024, Vol. 26 ›› Issue (3) : 224-229. DOI: 10.7499/j.issn.1008-8830.2309173

系列讲座——儿童矮身材的规范诊疗

过渡期生长激素缺乏症的管理

成胜权

作者信息 +

Management of transition growth hormone deficiency

CHENG Sheng-Quan

Author information +

文章历史 +

摘要

随着对生长激素缺乏症认识的不断深入，临床逐渐重视过渡期生长激素缺乏症（transition growth hormone deficiency, TGHD）的管理。TGHD诊治不足是主要的临床痛点，为规范TGHD诊治，国内外已发布了相关指南/共识。该文结合指南/共识和现有临床研究，总结了TGHD的评估、诊断、治疗和临床挑战，以期优化和进一步改善TGHD临床诊治和管理。

Abstract

With an increasing understanding of growth hormone deficiency, there has been a growing emphasis on the management of transition growth hormone deficiency (TGHD) in clinical practice. The inadequate diagnosis and treatment of TGHD have been a major clinical concern, leading to the development of relevant guidelines and consensus internationally. This article summarizes the evaluation, diagnosis, treatment, and clinical challenges of TGHD based on these guidelines, consensus, and existing clinical studies, aiming to optimize and further improve the clinical diagnosis, treatment, and management of TGHD.

导出引用

成胜权. 过渡期生长激素缺乏症的管理[J]. 中国当代儿科杂志. 2024, 26(3): 224-229 https://doi.org/10.7499/j.issn.1008-8830.2309173

CHENG Sheng-Quan. Management of transition growth hormone deficiency[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(3): 224-229 https://doi.org/10.7499/j.issn.1008-8830.2309173

参考文献

1 王丽. 生长激素缺乏症儿童的代谢异常研究进展[J]. 医药前沿, 2022, 12(32): 60-62.
2 中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 过渡期生长激素缺乏症诊断及治疗专家共识[J]. 中华儿科杂志, 2020, 58(6): 455-460. PMID: 32521956. DOI: 10.3760/cma.j.cn112140-20200314-00237.
3 Yuen KCJ, Alter CA, Miller BS, et al. Adult growth hormone deficiency: optimizing transition of care from pediatric to adult services[J]. Growth Horm IGF Res, 2021, 56: 101375. PMID: 33341524. DOI: 10.1016/j.ghir.2020.101375.
4 Mericq V, I?iguez G, Pinto G, et al. Identifying patient-related predictors of permanent growth hormone deficiency[J]. Front Endocrinol (Lausanne), 2023, 14: 1270845. PMID: 37881494. PMCID: PMC10597646. DOI: 10.3389/fendo.2023.1270845.
5 Tavares ABW, Collett-Solberg PF. Growth hormone deficiency and the transition from pediatric to adult care[J]. J Pediatr (Rio J), 2021, 97(6): 595-602. PMID: 33773961. PMCID: PMC9432185. DOI: 10.1016/j.jped.2021.02.007.
6 范婷婷, 程昕然. 过渡期生长激素缺乏症的研究进展[J]. 现代医药卫生, 2023, 39(7): 1175-1180. DOI: 10.3969/j.issn.1009-5519.2023.07.020.
7 Lee YJ, Choi Y, Yoo HW, et al. Metabolic impacts of discontinuation and resumption of recombinant human growth hormone treatment during the transition period in patients with childhood-onset growth hormone deficiency[J]. Endocrinol Metab (Seoul), 2022, 37(2): 359-368. PMIDPMID:35504604. PMCID: PMC9081298. DOI: 10.3803/EnM.2021.1384.
8 Ferruzzi A, Vrech M, Pietrobelli A, et al. The influence of growth hormone on pediatric body composition: a systematic review[J]. Front Endocrinol (Lausanne), 2023, 14: 1093691. PMID: 36843617. PMCID: PMC9947344. DOI: 10.3389/fendo.2023.1093691.
9 Tritos NA, Hamrahian AH, King D, et al. A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis[J]. Eur J Endocrinol, 2012, 167(3): 343-351. PMID: 22711759. PMCID: PMC4890184. DOI: 10.1530/EJE-12-0070.
10 Spaziani M, Tarantino C, Tahani N, et al. Clinical, diagnostic, and therapeutic aspects of growth hormone deficiency during the transition period: review of the literature[J]. Front Endocrinol (Lausanne), 2021, 12: 634288. PMID: 33716984. PMCID: PMC7943868. DOI: 10.3389/fendo.2021.634288.
11 Ahmid M, Ahmed SF, Shaikh MG. Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective[J]. Ther Clin Risk Manag, 2018, 14: 2283-2291. PMID: 30538484. PMCID: PMC6260189. DOI: 10.2147/TCRM.S136576.
12 Doknic M, Stojanovic M, Soldatovic I, et al. Mapping the journey of transition: a single-center study of 170 childhood-onset GH deficiency patients[J]. Endocr Connect, 2021, 10(8): 935-946. PMID: 34259648. PMCID: PMC8428021. DOI: 10.1530/EC-21-0274.
13 Hage C, Gan HW, Ibba A, et al. Advances in differential diagnosis and management of growth hormone deficiency in children[J]. Nat Rev Endocrinol, 2021, 17(10): 608-624. PMID: 34417587. DOI: 10.1038/s41574-021-00539-5.
14 ?amtosun E, ??klar Z, Berbero?lu M. Prospective follow-up of children with idiopathic growth hormone deficiency after termination of growth hormone treatment: is there really need for treatment at transition to adulthood?[J]. J Clin Res Pediatr Endocrinol, 2018, 10(3): 247-255. PMID: 29553045. PMCID: PMC6083473. DOI: 10.4274/jcrpe.0010.
15 Sbardella E, Pozza C, Isidori AM, et al. Endocrinology and adolescence: dealing with transition in young patients with pituitary disorders[J]. Eur J Endocrinol, 2019, 181(4): R155-R171. PMID: 31370006. DOI: 10.1530/EJE-19-0298.
16 Penta L, Cofini M, Lucchetti L, et al. Growth hormone (GH) therapy during the transition period: should we think about early retesting in patients with idiopathic and isolated GH deficiency?[J]. Int J Environ Res Public Health, 2019, 16(3): 307. PMID: 30678118. PMCID: PMC6388362. DOI: 10.3390/ijerph16030307.
17 Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care[J]. Endocr Pract, 2019, 25(11): 1191-1232. PMID: 31760824. DOI: 10.4158/GL-2019-0405.
18 中华医学会内分泌学分会. 成人生长激素缺乏症诊治专家共识（2020版）[J]. 中华内分泌代谢杂志, 2020, 36(12): 995-1002. DOI: 10.3760/cma.j.cn311282-20201130-00798.
19 Kim JH, Chae HW, Chin SO, et al. Diagnosis and treatment of growth hormone deficiency: a position statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology[J]. Endocrinol Metab (Seoul), 2020, 35(2): 272-287. PMID: 32615711. PMCID: PMC7386113. DOI: 10.3803/EnM.2020.35.2.272.
20 宋田田, 陈树春. 2019年美国《成人和从儿科向成人过渡患者生长激素缺乏症的管理指南》解读[J]. 中国实用内科杂志, 2020, 40(12): 1037-1041. DOI: 10.19538/j.nk2020120116.
21 Cannavò S, Cappa M, Ferone D, et al. Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement[J]. J Endocrinol Invest, 2023, 46(1): 189-200. PMID: 35960476. DOI: 10.1007/s40618-022-01880-w.
22 Henry RK. When they're done growing, don't forget they may still need growth hormone[J]. Metab Syndr Relat Disord, 2021, 19(5): 257-263. PMID: 33596132. DOI: 10.1089/met.2020.0130.
23 Touraine P, Polak M. Challenges of the transition from pediatric care to care of adults: "say goodbye, say hello"[J]. Endocr Dev, 2018, 33: 1-9. PMID: 29886491. DOI: 10.1159/000487521.
24 Yuen KCJ, Alter CA, Miller BS, et al. Adult growth hormone deficiency: optimizing transition of care from pediatric to adult services[J]. Growth Horm IGF Res, 2021, 56: 101375. PMID: 33341524. DOI: 10.1016/j.ghir.2020.101375.
25 Boguszewski MCS. Growth hormone deficiency and replacement in children[J]. Rev Endocr Metab Disord, 2021, 22(1): 101-108. PMID: 33029711. DOI: 10.1007/s11154-020-09604-2.
26 Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review[J]. Horm Res Paediatr, 2018, 90(4): 221-227. PMID: 30522126. DOI: 10.1159/000493211.
27 Hauffa BP, Touraine P, Urquhart-Kelly T, et al. Managing transition in patients treated with growth hormone[J]. Front Endocrinol (Lausanne), 2017, 8: 346. PMID: 29312142. PMCID: PMC5732460. DOI: 10.3389/fendo.2017.00346.
28 Assefi AR, Graham S, Crespo ML, et al. Evaluating the TUITEK? patient support program in supporting caregivers of children diagnosed with growth hormone deficiency in Argentina[J]. Front Endocrinol (Lausanne), 2023, 14: 1129385. PMID: 37091843. PMCID: PMC10117813. DOI: 10.3389/fendo.2023.1129385.
29 Wexler TL, Reifschneider K, Backeljauw P, et al. Growth hormone deficiency following traumatic brain injury in pediatric and adolescent patients: presentation, treatment, and challenges of transitioning from pediatric to adult services[J]. J Neurotrauma, 2023, 40(13-14): 1274-1285. PMID: 36825511. PMCID: PMC10294565. DOI: 10.1089/neu.2022.0384.
30 Bidlingmaier M, Gleeson H, Latronico AC, et al. Applying precision medicine to the diagnosis and management of endocrine disorders[J]. Endocr Connect, 2022, 11(10): e220177. PMID: 35968864. PMCID: PMC9513637. DOI: 10.1530/EC-22-0177.
31 Schnabel D, Kreitschmann-Andermahr I, Strasburger CJ, et al. Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol)[J]. Orphanet J Rare Dis, 2023, 18(1): 112. PMID: 37165422. PMCID: PMC10173596. DOI: 10.1186/s13023-023-02716-3.